0.68
+0.0264(+4.02%)
Currency In USD
| Previous Close | 0.66 |
| Open | 0.62 |
| Day High | 0.72 |
| Day Low | 0.61 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.31 |
| Volume | 6.49M |
| Average Volume | 7.2M |
| Market Cap | 22.22M |
| PE | -0.79 |
| EPS | -0.86 |
| Moving Average 50 Days | 0.5 |
| Moving Average 200 Days | 0.96 |
| Change | 0.03 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $56.96 as of November 05, 2025 at a share price of $0.684. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $513.91 as of November 05, 2025 at a share price of $0.684.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
GlobeNewswire Inc.
Nov 03, 2025 1:30 PM GMT
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 m
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
GlobeNewswire Inc.
Oct 22, 2025 1:00 PM GMT
--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permane
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
GlobeNewswire Inc.
Oct 16, 2025 1:00 PM GMT
Will Showcase Latest Fertility SolutionsSAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective